Drugs / MVA-BN Yellow Fever Vaccine
MVA-BN Yellow Fever Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02743455 | Jul 2016 → Mar 2018 | yellow fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN Yellow Fever Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743455 ↗ |
| Known as | Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever | “Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a...” NCT02743455 ↗ |
| Known as | MVA-BN-YF | “Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a...” NCT02743455 ↗ |
| Modality | Vaccine | “MVA-BN-YF vaccine” NCT02743455 ↗ |
| Route | Intramuscular | “as two doses intramuscularly on Day 1 and Day 29” NCT02743455 ↗ |